Breakthrough designation for Roche's Actemra in giant cell arteritis

5 October 2016

Swiss pharma giant Roche (ROG: SIX) has moved closer to gaining an additional indication for its rheumatoid arthritis drug Actemra (tocilizumab) – this time for giant cell arteritis (GCA).

The US Food and Drug Administration has granted the biologic, which is marketed as RoActemra in Europe, Breakthrough Therapy designation for GCA, a chronic, potentially life-threatening autoimmune condition caused by inflammation of large and medium-sized arteries, most often in the head, but also in the aorta and its branches.

Sandra Horning, chief medical officer and head of global product development at Roche, said: “The FDA breakthrough therapy designation for GCA underscores our continued commitment to explore Actemra in autoimmune diseases with significant unmet need.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK